Protalix Biotherapeutics is a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases.
The company is advancing promising candidates leveraging its expertise in protein therapeutics through its proprietary, commercial-scale ProCellEx® plant cell-based protein expression system, as well as its chemical and genetic modification capabilities, including PEGylation.
